Golden
OrbiMed

OrbiMed

U.S-based venture capital and private equity firm investing on life sciences companies worldwide.

All edits by  Khadidiatou Amirou 

Edits on 19 Mar 2019
Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 19 Mar 2019 2:03 pm
Edits made to:
Article (+8/-8 characters)

Article

OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San Francisco, California; Mumbai, India; ShanghaiShanghai, China; Herzliya, Israel and Hong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 19 Mar 2019 2:03 pm
Edits made to:
Article (+13/-13 characters)

Article

OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San FranciscoSan Francisco, California; Mumbai, India; Shanghai, China; Herzliya, Israel and Hong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 19 Mar 2019 2:03 pm
Edits made to:
Article (+13/-13 characters)

Article

OrbiMed focuses on funding companies in the field of life sciences. The firm invests globally, with past investments on companies based in North AmericaNorth America, Europe, and Asia (China, India, and Israel). The firm finances companies at various stages of development, from seed to buyouts. Its most recent funding round raised $551 million on September 2017.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 19 Mar 2019 2:03 pm
Edits made to:
Article (+4/-4 characters)

Article

OrbiMed focuses on funding companies in the field of life sciences. The firm invests globally, with past investments on companies based in North America, Europe, and AsiaAsia (China, India, and Israel). The firm finances companies at various stages of development, from seed to buyouts. Its most recent funding round raised $551 million on September 2017.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 19 Mar 2019 2:03 pm
Edits made to:
Article (+9/-9 characters)

Article

OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San Francisco, California; Mumbai, India; Shanghai, China; Herzliya, Israel and Hong KongHong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 19 Mar 2019 2:03 pm
Edits made to:
Article (+6/-6 characters)

Article

OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San Francisco, California; MumbaiMumbai, India; Shanghai, China; Herzliya, Israel and Hong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Khadidiatou Amirou
Khadidiatou Amirou approved a suggestion from Golden's AI on 19 Mar 2019 2:03 pm
Edits made to:
Article (+8/-8 characters)

Article

OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San Francisco, California; Mumbai, India; Shanghai, China; HerzliyaHerzliya, Israel and Hong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Khadidiatou Amirou
Khadidiatou Amirou edited on 19 Mar 2019 2:01 pm
Edits made to:
Infobox (+1 properties)
Description (+97/-149 characters)
Article (+956 characters)
Categories (+1 topics)
Topic thumbnail

OrbiMed

OrbiMed is a healthcare management fund specializing in biopharmaceuticals that is Headquartered in New York City, New York and was founded in 1989.

U.S-based venture capital and private equity firm investing on life sciences companies worldwide.

Article



OrbiMed, also known as OrbiMed Advisors, is a private equity and venture capital firm established in 1989. The firm was founded by Carl L. Gordon and Sven H. Borho. Its headquarters is located in New York City, New York and it has additional offices in San Francisco, California; Mumbai, India; Shanghai, China; Herzliya, Israel and Hong Kong. As of March 2019, the firm is managing 152 companies in its current portfolio and has sold off its ownership in 205 companies. Its most recent investment was for Imara on March 2019, a company developing therapeutics for sickle cell disease treatment.

Funding

OrbiMed focuses on funding companies in the field of life sciences. The firm invests globally, with past investments on companies based in North America, Europe, and Asia (China, India, and Israel). The firm finances companies at various stages of development, from seed to buyouts. Its most recent funding round raised $551 million on September 2017.

Infobox

Categories

No more activity to show.